Methoxphenidine


Chemical Data :

IUPAC: (±)-1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine

CAS: 127529-46-8 Yes

ChemSpider: N/A

Molecular Weight: 295.4186

Molecular Formula: C20H25NO


MXP, also known as Methoxphenidine or 2-MeO-Diphenidine, is a dissociative and hallucinogenic drug compound of the diarylethylamine class. It is reported to induce a dissociative anesthesia in a similar mannar to the arylcyclohexylamines (PCP, Ketamine) and the morphinans (DXM).

MXP was listed in a patent in 1989 as a potential drug compound for use in treatment of neurotoxic brain injuries.

In 2013 the UK issued a blanket ban on the arylcyclohexylamines including all derivatives and analogues of ketamine and PCP which were growing in popularity. This subsequently led to the introduction of MXP in to the market as a possible legal alternative. It has been sold online in powder and tablet forms.

MXP goes by the formal and systematic IUPAC name (±)-1-[1-(2-methoxyphenyl)-2-phenylethyl]piperidine.

One way of approaching the structure of MXP is to describe it as a highly substituted phenethylamine. The phenethylamine backbone, common to amphetamines and the cathinones, is present. This is a six member aryl ring with an amine bound to it via an ethyl bridge. In MXP the amine is transformed in to a six member unsaturated piperidine ring.  The ethyl backbone is substituted at the alpha carbon with an additional aryl ring that has a methoxy substitution at carbon number two. In total then there are three ring structures. MXP can be said to be a piperadine dissociative. It is an analogue of the piperadine dissociative Diphenidine, with MXP having the same structure, plus an additional 2 methoxy substitution.

In pharmacological terms MXP is known to acts as an NMDA antagonist, similar to ketamine and PCP. This interaction is what gives these compounds their anaesthetic qualities. It is further speculated that MXP might have some involvement in the dopaminergic pathways, perhaps acting as a dopamine reuptake inhibitor, which would account for the reported physical and cognitive euphoria.

The toxicological profile of MXP in humans is not known. The health effects of short term or long term recreational use have yet to be understood.

MXP is not for human or animal consumption.

Unverifiable online reports provide some insight as to the subjective effects of this compound.

The physical effects that users report are most analogous to the dissociative DXM than any other common dissociative. Effects of MXP are said to become more intense with higher dosages.

Users report feelings of disconnection from their senses. Physical disconnection from the environment is reported by some to be much more “controllable” than other comparable dissociatives.  The “body high” has been described as a pleasurable vibrating sensation which spreads to encompass the body in a soft feeling which intensifies to a peak and then dissipates at offset.

Users also report feelings of numbness at their extremities and loss of fine and gross motor control. It is common to lose balance and hand eye coordination.  People are recommended to remaining sitting to avoid risk of falling over.

Distinct feelings of physical and mental euphoria are reported. Also mentioned in reports are feelings of depersonalisation, disconnection of the conscious mind, derealisation and suppression of memory and anxiety.